Table 1 Patients receiving second-line therapy in randomised clinical studies (adapted from Grothey et al, 2004)

First-line regimen	Patients with second-line therapy (%)	Patients administered three active drugs (%)	Median overall survival (months)	Reference
Irinotecan+bolus 5-FU/LV	52	5	14.8	Saltz et al (2000)
Irinotecan+bolus 5-FU/LV	67	24	15.0	Goldberg et al (2004)
Irinotecan+CIV 5-FU/LV	39	16	17.4	Douillard et al (2000)
Irinotecan+AIO	56	52	20.1	Köhne et al (2005)
Irinotecan+CIV 5-FU/LV	81	74	21.5	Tournigand et al (2004)
FOLFOX4	58	30	16.2	de Gramont et al (2000)
FOLFOX4	75	60	19.5	Goldberg et al (2004)
FOLFOX6	62	74	20.6	Tournigand et al (2004)
FOLFOX7	73	61	21.2	Tournigand et al (2006)

AIO=Arbeitsgemeinschaft für Internistische Onkologie; CIV=continuous intravenous infusion; FOLFOX=5-FU/LV+oxaliplatin; 5-FU=5-fluorouracil; LV=Leucovorin^®.

Quick links

Search